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Abstract
S-acylation, the covalent attachment of palmitate and other fatty acids on cysteine residues, is a reversible post-translational
modification that exerts diverse effects on protein functions. S-acylation is catalyzed by protein acyltransferases (PAT), while
deacylation requires acyl-protein thioesterases (APT), with numerous inhibitors for these enzymes having already been
developed and characterized. Among these inhibitors, the palmitate analog 2-brompalmitate (2-BP) is the most commonly
used to inhibit palmitoylation in cells. Nevertheless, previous results from our laboratory have suggested that 2-BP could
affect protein deacylation. Here, we further investigated in vivo and in vitro the effect of 2-BP on the acylation/deacylation
protein machinery, with it being observed that 2-BP, in addition to inhibiting PAT activity in vivo, also perturbed the
acylation cycle of GAP-43 at the level of depalmitoylation and consequently affected its kinetics of membrane association.
Furthermore, 2-BP was able to inhibit in vitro the enzymatic activities of human APT1 and APT2, the only two thioesterases
shown to mediate protein deacylation, through an uncompetitive mechanism of action. In fact, APT1 and APT2 hydrolyzed
both the monomeric form as well as the micellar state of the substrate palmitoyl-CoA. On the basis of the obtained results,
as APTs can mediate deacylation on membrane bound and unbound substrates, this suggests that the access of APTs to the
membrane interface is not a necessary requisite for deacylation. Moreover, as the enzymatic activity of APTs was inhibited
by 2-BP treatment, then the kinetics analysis of protein acylation using 2-BP should be carefully interpreted, as this drug also
inhibits protein deacylation.
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Introduction
Fatty-acylated peripheral proteins, such as members of the small
G-protein Ras family, the neuronal proteins PSD-95 and growth-
associated protein-43 (GAP-43) [1–5], are synthesized in the
cytosol and post-tranlationally modified by different lipid moieties
[6–8], with these modifications governing their membrane
association and membrane subdomain segregation, as well as
their trafficking, function and stability [9,10].
Despite the many post-translational lipid modifications of
proteins that have been achieved, including isoprenylation and
myristoylation, the addition of fatty acid to the sulfhydryl group
of a cysteine to form a thioester bond (S-acylation, often
referred as palmitoylation) is the only known readily reversible
linkage that has a much shorter half-life than that of the protein
itself [11–16]. Consequently, S-acylation can operate as a
switch, regulating not only the protein-membrane binding
affinity and segregation, but also modulating the proteins
biological activities [17–19]. S-acylation is catalyzed by protein
acyltransferases (PATs) whereas deacylation requires acyl-protein
thioesterases (APTs).
PATs have been identified both in yeast and mammals [20,21]
and have a 51-amino-acid domain containing a DHHC (aspartate-
histidine-histidine-cysteine) motif and a high abundance of
cysteine residues. Additionally, a novel and conserved 16-amino-
acid motif present at the cytosolic C-terminus of PATs was
recently identified to be required for protein acylation mediated by
PAT [22]. The mammalian and yeast genomes encode up to 24
and 7 PATs, respectively, which are integral membrane proteins
predicted to contain 4 to 6 transmembrane domains. S-acylation
has been reported to occur in several membrane compartments
[1,23–25] with apparent substrate selectivity. However, S-acyla-
tion of semisynthetic substrates is detectable only in the Golgi
complex with substrate specificity not being essential for the
reacylation step [26,27].
The enzymes mediating deacylation have not been character-
ized as extensively as the PATs, and only two cytosolic APTs have
been described to date: APT1 and APT2, which were originally
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isolated as lysophospholipases and later demonstrated to be
effective as protein thioesterases [19,28–30]. Although APTs
mediate fatty acid turnover on many cytoplasmic proteins, such as
heterotrimeric G protein a subunits, endothelial nitric-oxide
synthase, SNAP-23, GAP-43 and H-Ras, it has been demonstrated
that APT1 and APT2 are more selective. For instance, caveolin
and GAP-43 are not deacylated by APT1 [29,31], calcium-
activated potassium channel is not deacylated by APT2 [32] and
not all substrates are deacylated with the same efficiency [33].
After the discovery and initial characterization of PATs and
APTs, it has become of increasing interest to develop pharmaco-
logic inhibitors for these enzymes. This is based on the necessity to
modulate the localization and activity of many important
intracellular acylated proteins, several of which are involved in
pathological processes, with most of the research in this area
having been focused on the H- and N-Ras proteins, as they play a
causative role in melanoma, leukemia and cancers of the liver and
kidney. However, lipid based inhibitors of S-acylation have been
limited to 2-brompalmitate (2-BP), cerulenin and tunicamycin
[34], among which, 2-BP is the most commonly used to inhibit S-
acylation in cells [5,29,35,36] and PAT activity in vitro [37,38].
More recently, several non-lipid inhibitors have also been
identified by high throughput screening [39] and are now being
further characterized [38].
The palmitate analog 2-BP is a electrophilic a-brominated fatty
acid which has been widely used to inhibit the palmitoylation of
several proteins, including the H-Ras, GAP-43 and Rho family
kinases [5,36,40]. In fact, 2-BP acts as a general inhibitor of
palmitate incorporation and does not appear to selectively inhibit
the acylation of specific protein substrates. It was also found to
inhibit fatty acid CoA ligase and other enzymes involved in lipid
metabolism, thus affecting the levels of intracellular palmitoyl-
CoA, a necessary donor substrate for S-acylation [41].
During the course of previous experiments carried out in our
laboratory to investigate the mechanisms of GAP-43 membrane
affinity, it was observed that PAT inhibition with 150 mM 2-BP
completely eliminated acylation of newly synthesized GAP-43, and
consequently its binding to the membranes. However, at steady-
state conditions, 2-BP treatment did not modify the acylation state
or membrane binding properties of GAP-43 [5], thereby strongly
suggesting that membrane-associated GAP-43 was not being
deacylated and that 2-BP not only inhibits PATs but also APT
activity. Some subsequent experiments were therefore conducted
at lower concentrations of 2-BP in order to inhibit the PATs and
minimally affecting the deacylating enzyme activities [29].
Taking into consideration that 2-BP is widely used to inhibit
protein palmitoylation and that it is sometimes referred to as a
‘‘specific’’ inhibitor of acylation, we considered it essential to
investigate further the in vivo and in vitro effects of 2-BP on the
acylation/deacylation protein machinery, by paying particular
attention to the deacylation enzymatic process. Briefly, we
observed that 2-BP in vivo, in addition to inhibiting PAT activity,
also perturbed the acylation cycle of GAP-43 at the level of
deacylation. Next, the study was extended to evaluate the ability of
2-BP to affect the enzymatic activities of recombinant human
APT1 and APT2 in vitro. Interestingly, both thioesterases showed
a significant profile of inhibition by 2-BP. On the basis of these
results, we concluded that 2-BP treatment inhibits the APT1 and
APT2 activities both in vitro and in vivo. This not only implies
that the kinetics analysis of protein acylation using 2-BP should be
carefully interpreted because this drug also inhibits protein
deacylation, but also suggests that the 2-BP moiety can be used
as a model for the rational design of new drugs that may be able to
modify the oncogenic signaling of acylated proteins (i.e. N- and H-
Ras), which may lead to the development of new therapies for
cancer.
Results
2-BP Inhibits PAT Activity and hence the Membrane
Association of a Single Acylated Protein
To investigate in vivo the effect of 2-BP on the acylation/
deacylation protein machinery, we set up a direct method for
acylation/deacylation readout using a monoacylated mutant of
GAP-43, which requires a single acylation event for its membrane
association. GAP-43 is a dually palmitoylated protein found in
cysteine residues at positions 3 and 4. As previously observed, the
acylation motif (MLCCMRRTKQVEK) of GAP-43 (N13GAP-43)
fused to the N-terminal domain of spectral variants of green
fluorescent protein (GFP) localized at steady-state at the recycling
endosome, plasma membrane and trans Golgi network (TGN)
[5,29]. The point mutation at Cys3 in N13GAP-43 [N13GAP-
43(C3S)] caused an accumulation at the cytosol and TGN, which
disrupted recycling endosome association but did not affect plasma
membrane association [5,29].
The effect of 2-BP on the acylation of newly synthesized
N13GAP-43(C3S) was tested after synchronized protein expression
in Chinese hamster ovary (CHO)-K1 cells (Fig. 1A). In control
conditions, the newly synthesized GAP-43(C3S)-YFP associated to
TGN membranes due to S-acylation by TGN resident PATs [5].
However, treatment with 25, 50 and 150 mM 2-BP inhibited
membrane association, especially to TGN, of N13GAP-43(C3S)
(Fig. 1B), an observation which is in agreement with the notion
that 2-BP inhibits protein acylation. To support the confocal
microscopy experiments, membrane association and the extent of
the post-translational modification of N13GAP-43(C3S) were
determined at the same experimental conditions by ultracentrifu-
gation. It was found that 2-BP, when compared to control
conditions, caused a significant decrease of membrane boun-
ded-N13GAP-43(C3S) at all analyzed concentrations (25, 50 and
150 mM) (Fig. 1C). Overall, these biochemical results are in close
agreement with those obtained by confocal microscopy analysis
and clearly indicate that 2-BP inhibits PAT activity and
consequently the membrane binding of N13GAP-43(C3S).
2-BP Perturbs the Deacylation Kinetics of Monoacylated
GAP-43
Having demonstrated that 2-BP inhibited PAT activity in vivo
at a range of concentrations between 25 and 150 mM, we next
investigated whether the a-brominated fatty acid could also
perturb the deacylation kinetics of monoacylated GAP-43 at the
same concentrations. Thus, CHO-K1 cells transiently coexpres-
sing N13GAP-43(C3S) and GalNAc-T (TGN marker) were treated
with 25, 50 and 150 mM 2-BP (2-BP) or dimethylsulfoxide
(DMSO, Control) and the GAP-43 subcellular distribution was
monitored at different times by live cell confocal fluorescent
microscopy, with cycloheximide (CHX) and protein degradation
inhibitors being incorporated to the culture medium 1 h before
and during 2-BP treatment (Fig. 2A). In control cells, the amount
of TGN-membrane association of GAP-43(C3S) did not signifi-
cantly change over time, whereas in cells treated with 25 mM 2-
BP, the TGN-associated fraction of GAP-43 significantly de-
creased over time with a half-life of 3.560.1 min (Fig. 2B, C and
D; and movie S1). Interestingly, a significant reduction in the
N13GAP-43(C3S) depalmitoylation rate was clearly observed at
higher 2-BP concentrations (Fig. 2B). The calculated half-life of
the TGN-associated fraction of GAP-43(C3S) in cells treated with
50 and 150 mM 2-BP was 5.460.3 and 8.860.2 min, respectively
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(Fig. 2C and D; and movie S1). However, the observed decrease of
the TGN-membrane association of GAP-43(C3S) in 2-BP
conditions was not attributable to TGN membrane redistribution
since the TGN marker GalNAc-T was not affected under these
experimental conditions (Fig. 2E) nor due to an increase in the
TGN to plasma membrane vesicular transport of N13GAP-
43(C3S), since all experiments were performed at 20uC, a
condition which drastically decreases this process [5].
Finally, the effect of 2-BP on membrane association of wild-type
diacylated GAP-43 was evaluated (Fig. 3). Interestingly, it was
observed that in cells treated up to 6 h with 150 mM 2-BP the
membrane association of GAP-43 did not significantly change
compared to control conditions. In contrast, when cells were
treated with 25 and 50 mM 2-BP there was a significant amount of
soluble GAP-43 at 3 h, with this being more evident at 6 h. Taken
together, these results indicate that 2-BP, in addition to its
demonstrated inhibition of protein acylation, can also perturb the
protein deacylation in vivo, probably by affecting the catalytic
proprieties of thioesterases.
Enzymological Characterization and Effect of 2-BP on
Human APT1 and APT2 Activities
Up to this point, our results indicate that 2-BP perturbs
deacylation in living cells. Therefore, we investigated the effect
of 2-BP on the activities of recombinant human APT1 and
APT2, which are the only two bona fide thioesterases that have
been shown to mediate deacylation [19,29]. First, both human
thioesterases were expressed in Escherichia coli, purified to
apparent homogeneity and biochemically characterized (Fig. 4).
As observed in Figure 4A and B, both APT1 and APT2
migrated with an apparent molecular mass of 26 kDa. Then, to
test whether both recombinant proteins were enzymatically
actives, we evaluated their ability to hydrolyze palmitoyl-CoA,
which is a substrate widely used to measure thioesterases. It was
observed using a dose-response curves that APT1 and APT2
hydrolyzed palmitoyl-CoA with Km values of 0.14 and
0.35 mM, respectively (Fig. 4C). Interestingly, both enzymes
hydrolyzed the monomeric form as well as the micellar state of
the substrate palmitoyl-CoA (CMC 100–180 mM), although at
Figure 1. 2-BP inhibits acylation and membrane association of newly synthesized N13GAP-43(C3S). A) Schematic representation of the
experimental procedure used in B and C. The CHO-K1 cells were transfected at 28 h with the plasmid encoding N13GAP-43(C3S)-YFP. At 30 min
before CHX withdrawal (-CHX), cells were incubated with 25, 50 or 150 mM 2-BP or DMSO (vehicle, Control). At 0 h, CHX was removed and cells were
further incubated with 2-BP at the concentrations indicated above, or with DMSO, at 37uC for 9 h. Finally, cells were analyzed by confocal fluorescent
microscopy or subjected to biochemical assays. B) Representative images showing the effect of 2-BP or DMSO (Control) on the TGN association of
N13GAP-43(C3S). The fluorescent signal from YFP was pseudocoloured gray. The inset shows details of the boxed area at a higher magnification. Scale
bars: 5 mm. C) After treatment with 2-BP, CHO-K1 cells transiently expressing N13GAP-43(C3S)-YFP were lysed, ultracentrifuged and the supernatant
(S) and pellet (P) fractions were recovered. Proteins from these fractions were western blotted with an antibody to GFP (a-GFP) and a-tubulin (a-tub).
doi:10.1371/journal.pone.0075232.g001
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higher concentrations of this substrate the deacylation mediated
by APTs was inhibited (Fig. 5A and B). These results are of
biological relevance, since both thioesterases are mainly
expressed in the cytoplasm with a high hydrophilic character
(Fig. 6) and might catalyze the hydrolysis of both soluble and
membrane-bound substrates. Moreover, it also implies that the
structure of the substrate, which depends on the membrane
microenvironment, is important in determining the deacylation
kinetics, which was also further investigated by Small-angle X-
ray scattering (SAXS) analysis (Fig. 5C). As expected, no
aggregation of palmitoyl-CoA was observed at 50 mM. Howev-
er, micellar aggregation was evident at both 300 and 600 mM.
Interestingly, at 1775 mM palmitoyl-CoA the SAXS curve
changed its shape, indicating that a new kind of aggregate
appeared that was compatible with globular micelles (for
additional information and analysis see the legend of Fig. 5C).
As this occurred in the range of substrate concentration at
which the APT activity was lost (Fig. 5A and B), it probably
indicates that changes in the structure of the lipid substrate
severely affected the enzyme-substrate interaction. However, this
Figure 2. Deacylation kinetic of N13GAP-43(C3S) at different doses of 2-BP. A) Schematic representation of the experimental procedure
used in B, C and E. The CHO-K1 cells expressing N13GAP-43(C3S)-YFP, 72 h after transfection, were treated at 20uC with 25, 50 or 150 mM 2-BP or
DMSO (Control) in the presence of CHX and protein degradation inhibitors which were added 1 h before imaging and during all the experiments. The
N13GAP-43(C3S) subcellular distribution was analyzed by live cell confocal microscopy. B) Representative images showing the effect of different doses
of 2-BP or DMSO (vehicle, Control) on the TGN-membrane association of N13GAP-43(C3S)-YFP. The fluorescent signal from YFP (pseudocoloured gray)
at 0, 5, 15 and 30 min after 2-BP or vehicle addition is shown. The insets show the expression of the TGN marker GalNAc-T-CFP (pseudocolored gray).
Cell boundaries (white lines) are indicated. C) Quantification of the images shown in B (for details see Materials and methods). Curves were fitted to
the exponential decay function for each data set, and data are expressed as means6SEM for a representative experiment from nine independent
ones. D) The half-life for deacylation at each 2-BP dose calculated from the C data (n = 6). (*p,0.05; ***p,0.0001; compared to 25 mM). E)
Representative images showing the effect of 50 mM 2-BP on the TGN-membrane association of GalNAc-T-YFP over time. The fluorescent signal from
YFP (pseudocoloured gray) at 0, 5, 15 and 30 min after 2-BP addition is shown. Scale bars: 5 mm.
doi:10.1371/journal.pone.0075232.g002
Figure 3. Deacylation kinetic and membrane association of GAP-43 at different doses of 2-BP. CHO-K1 cells coexpressing diacylated
GAP-43-YFP and GalNAc-T-CFP were treated with 25, 50 or 150 mM 2-BP or vehicle (DMSO, Control), and the GAP-43 subcellular distribution was
analyzed by live cell confocal microscopy at the indicated times. CHX and protein degradation inhibitors were added and maintained in the culture
media until the end of each experiment. Representative images show the effect of different doses of 2-BP on the membrane association of GAP-43.
The fluorescent signals from YFP and CFP were pseudocoloured green and red, respectively. Scale bars: 5 mm.
doi:10.1371/journal.pone.0075232.g003
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phenomenon was not observed when the zwitterionic detergent
CHAPS was present in the reaction (Fig. 5A and B), which
eventually led to the formation of mixed micelles [13].
After biochemical and enzymological characterization of
recombinant human APT1 and APT2, we next evaluated the
effect of 2-BP on their enzymatic activities. As shown in Figure 7, a
drastic and significant reduction of APT1 activity was observed at
50 and 100 mM 2-BP, with the molecular mechanism of inhibition
appearing to be of an uncompetitive type with the apparent Vmax
and Km values reduced. Thus, according to this type of enzymatic
inhibition, 2-BP would be expected to bind to the enzyme-
substrate complex. In the case of APT2, there was a significant
effect of 2-BP on its enzymatic activity, reaching 17% and 30%
inhibition at 50 and 100 mM 2-BP, respectively.
Discussion
In the present study we have shown that in vivo treatment
with 2-BP, in addition to inhibiting PAT activity, also perturbed
the turnover of palmitate moieties on GAP-43 by inhibiting the
acyl-protein thioesterases. In particular, it was observed that 2-
BP strongly inhibited PAT activity over a range of concentra-
tions from 25 mM to 150 mM. In addition, the TGN-associated
fraction of N13GAP-43(C3S), which is highly dependent on the
acylation state of the protein, significantly decreased over the
time of 2-BP treatment, revealing a half-life of membrane
association which is directly proportional to the 2-BP concen-
tration. A similar result was also observed for the diacylated
wild-type GAP-43.
The electrophilic a-brominated fatty acid 2-BP, which is highly
reactive toward thiols, has been demonstrated to alkylate many
membrane-bound proteins through non-specific and non-compet-
itive mechanisms [41]. Although the precise way in which 2-BP
exerts this effect is unknown, taking into account the hydrophobic
nature of 2-BP, it seems likely that the brominated inhibitor inserts
itself into the lipid bilayer and gains access to membrane-bound
proteins. In the same way, the soluble proteins that interact with
the interface may also be modified by 2-BP. Additionally, 2-BP
might act indirectly by modifying the surrounding lipid environ-
ment, and hence affect the catalytic properties of integral
membrane proteins, such as the PATs. It is also known that 2-
BP is converted to 2-BP-CoA inside the cell, which is a non-
Figure 4. Purification and biochemical characterization of recombinant human APT1 and APT2. A) Coomasie blue staining (left) or
western blot (right) of supernatant fractions obtained from E. coli transformed with His-APT1, His-APT2 or the empty vector (C). Recombinant proteins
were analyzed using an antibody to Hisx6 tag. B) Coomassie blue staining of recombinant APT1 and APT2 was obtained by affinity chromatography
and analyzed by SDS-PAGE. Molecular masses of the markers in kDa are indicated on the right. C) The initial rate of palmitoyl-CoA hydrolase activity
was measured with 0.5 mg of recombinant APT1 or APT2. The data shown are representative experiments performed in triplicate. Curves were fitted
to the Michaelis-Menten rate equation for each data set, and the kinetic parameters are shown in the table.
doi:10.1371/journal.pone.0075232.g004
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metabolizable molecule, and the binding of 2-BP to PATs could
result in formation of an inhibitor:enzyme complex, thereby
affecting the transfer of 2-BP to the acceptor protein. Importantly,
2-BP may also alter lipid metabolism in general, and protein
acylation in particular, by reducing the level of intracellular
palmitoyl-CoA, which is a necessary donor substrate for
palmitoylation [34,35]. In consequence, evidences indicate that
2-BP exerts multiples, and probably cumulative, effects on the
cellular metabolism.
The enzymological analysis performed in this work with
recombinant human APTs clearly indicates the significant profile
of inhibition of 2-BP. These assays permit us to speculate that the
brominated fatty acid is probably perturbing the thioesterase
activities through an uncompetitive mechanism resulting from a
direct modification of the enzyme, possibly by alkylation.
Recently, it was reported that APT1 and APT2 undergo
palmitoylation on cisteine-2 [42], which was suggested to facilitate
the steady-state membrane localization and function of these
thioesterases. Nevertheless, experimental evidence obtained in our
laboratory by biochemical and cell biology assays in CHO-K1
cells has demonstrated that both enzymes are mainly cytosolic with
a high hydrophilic character (Fig. 6). Consequently, it is highly
probable that non-acylated APTs could transiently associate with
the interface in order to exert their catalytic activities. In line with
Figure 5. Dose-response curve for APT activities following different concentrations of palmitoyl-CoA and the structural
characterization of the substrate by SAXS analysis. The initial rate of palmitoyl-CoA hydrolase activity was measured with 0.5 mg of
recombinant APT1 (A) or APT2 (B), both in control conditions (-CHAPS -Mg2+, left bars) or in the presence of 7.5 mM CHAPS and 2 mM MgCl2
(+CHAPS +Mg2+, right bars) at 150, 300, 600 and 1500 mM. Data show the initial rate of the reaction (V, mM/min) at different concentrations of
palmitoyl-CoA (P-CoA), which are from representative experiments performed in triplicate. C) SAXS analysis. Palmitoyl-CoA was resuspended in buffer
(50 mM Hepes, pH 8.0) at 50, 300, 600 and 1775 mM, and measurement were carried out as indicated in Materials and methods. The figure shows the
SAXS raw data (after subtraction of the buffer background and the concentration normalization) for increasing concentrations of palmitoyl-CoA. As
can be seen, no noticeable diffraction peak (due to any strong correlation) is observed in any of the curves. The curve for 50 mM palmitoyl-CoA does
not display any obvious tendencies. The curves for 300 and 600 mM show increasing intensity at a very low angle, adopting similar slopes and
absolute values. The curve at 1775 shows a different behavior with an increment at a low angle, which reached a plateau below 0.3 nm21 with a
prominent bump centered at 1.6–1.7 nm21 (very common in bilayers and micelles). In agreement with the wedge-shaped molecular structure, this
molecule did not display the global form factor of bilayers, but rather one of the micelles. This is evident from the non-quadratic decay of the
intensity as a function of q. The saturation value at low q (Guiniers approximation) for the 1775 mM may indicate globular micelles. The clear
differences present between the curves at 300–600 mM and the one at 1775 mM is probably due to the fact that the micelles have a different
geometry, with the decay at low q values (q,0.5 nm21) having a finite slope closer to an inverse (first power) behavior, suggesting rod-like
structures.
doi:10.1371/journal.pone.0075232.g005
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this assumption, recombinant APT1 and APT2 (which are not
acylated when expressed in bacteria) hydrolyze the substrate
(palmitoyl-CoA) both in its monomeric form or micellar state. In
contrast to what has been reported for certain enzymes with
membrane-associated substrates (i.e., phospholipases and lipases)
[43,44], we observed that the APTs do not display interfacial
activation, as was previously observed for APT1 activity over lyso-
phosphocholine [45]. However, various results do indicate that
changes in the structure of the lipid substrate drastically affect the
APTs-substrate interaction.
Using confocal and video fluorescence microscopy on living
cells, we demonstrated that the kinetic of deacylation of the
monoacylated N13GAP-43, even at the highest 2-BP concentra-
tion, was clearly much faster (minutes) than its wild-type diacylated
counterpart (hours). A similar behavior has also been observed in
two isoforms of Ras GTPases [11,15,46]. The half-life of palmitate
on N-Ras (monoacylated) is 20 min and for H-Ras (diacylated) is
2.4 h, with a simple interpretation being that the double acylation
is responsible for this longer half-life of palmitate and suggesting
that monoacylated species are the preferred substrates for
thioesterases. However, it should be mentioned that at steady-
state conditions the monopalmitoylated fraction of GAP-43
represents 60% of the total GAP-43 protein [47], suggesting that
the double palmitoylation is not an efficient mechanism of
acylation in vivo. Consequently, we hypothesize that an important
physiological role for APT could be in deacylating single acylated
substrates, which should later be in condition to perform another
cycle of acylation, or eventually, be sorted for degradation via the
ubiquitin-proteasome system [29,48,49].
Summing up, our results indicate that 2-BP should be used
carefully in the study of the role of PATs in the regulation of
protein palmitoylation and function, thus avoiding an erroneous
interpretation of kinetic analysis, due to this drug also inhibiting
protein deacylation. Nevertheless, controlled experimental condi-
tions using 2-BP could be beneficial in order to ‘‘freeze’’ the
turnover of palmitate on palmitoylated proteins, which may
Figure 6. Analysis of acyl-protein thioesterase expression in
CHO-K1 cells and biochemical characterization. A) CHO-K1 cells
transiently expressing APT1-YFP (APT1) or APT2-YFP (APT2) were
analyzed by confocal microscopy (pseudocoloured gray). B) CHO-K1
cells expressing APT1-YFP (APT1) or APT2-YFP (APT2) were lysed,
ultracentrifuged and the supernatant (S) and pellet (P) fractions were
recovered. Proteins from these fractions were western blotted with an
antibody to GFP (a-GFP). C) CHO-K1 cells transiently expressing APT1-
YFP (APT1) or APT2-YFP (APT2) were lysed, ultracentrifuged, and the
supernatant (S) and pellet (P) fractions were isolated. Buffer containing
1% v/v Triton X-114 was added to the samples and phase separation
was induced at 37uC. Proteins from the A (aqueous) and D (detergent)
phases were western blotted with an antibody to GFP (a-GFP) and a-
tubulin (a-tub). The Triton X-114 partition assay was performed as
described by [29]. Note that APT1 and APT2 are mainly present in the
aqueous phase of the supernatant (S) fraction, clearly demonstrating
their hydrophilic character. Scale bars: 5 mm.
doi:10.1371/journal.pone.0075232.g006
Figure 7. In vitro inhibition of APT1 by 2-BP. A) The initial rate of
palmitoyl-CoA hydrolase activity was measured with 0.5 mg of
recombinant APT1 in the presence of 50 or 100 mM 2-BP or DMSO
(vehicle), with the APT1 activity of control condition (vehicle) taken as
100%. B) The initial rate of palmitoyl-CoA hydrolase activity (mM/min)
was measured with 0.5 mg of recombinant APT1 in the presence of
50 mM 2-BP (+2-BP) or in the presence of DMSO (vehicle, 22-BP). The
data shown are representative experiments performed in triplicate.
Curves were fitted to the Michaelis-Menten rate equation for each data
set. The kinetic parameters (Km and Vmax) are shown in the table
below the figure.
doi:10.1371/journal.pone.0075232.g007
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permit investigation into the importance of deacylation in the
function of these proteins. One such example is Ras, whose
deacylation is important for its correct subcellular distribution and
function [25,50]. Our laboratory and other researchers have
previously reported that APT1 and APT2 deacylate H-Ras
[13,29], and APTs have been used as molecular targets in the
development of drugs to impair Ras signaling [51,52]. The finding
reported in the present work that 2-BP has also the potential to
inhibit APT1 and APT2 activity, implies that this moiety can be
used as a model for the rational design of new drugs that may be
able to modify the oncogenic signaling of Ras, and consequently,
might lead to the development of new therapies for cancer.
Materials and Methods
Plasmids
The expression vectors pECFP-C1 (where ECFP is enhanced
cyan fluorescent protein) and pEYFP-N1 (where EYFP is
enhanced yellow fluorescent protein) were from Clontech (CA,
USA). Expression plasmids for N13GAP-43(C3S)-YFP, N27Gal-
NAc-T-CFP, APT1-Cherry and APT2-Cherry have been previ-
ously described [5,29,53].
Cell Culture and DNA Transfections
CHO-K1 cells (ATCC, Manassas, VA, USA) were maintained
at 37uC, 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
antibiotics (ATB, 100 mg/ml penicillin and 100 mg/ml strepto-
mycin). Cells grown on Petri dishes were used for both live cell
imaging and western blot experiments. These cells were transfect-
ed with 0.8–1.5 mg/35 mm dish of the indicated plasmid using
cationic liposomes (Lipofectamine, Invitrogen, CA, USA) or
polyethyleimine (PEI, Sigma-Aldrich, St. Louis, MO, USA). At
24 h after cell transfeccion, cells were processed for western blot
experiments or plated onto Lab-Tek chambered coverglass
(Thermo Scientific Nunc, IL, USA), incubated for 24 h, and then
used in live cell imaging.
2-BP Treatment
A stock solution of 2-BP (0.42 M, Fluka, Sigma-Aldrich, St.
Louis, MO, USA) was prepared in DMSO. To analyze the effect
of 2-BP on the steady-state subcellular distribution of fluorescent
proteins by live cell imaging experiments, CHO-K1 cells were
treated with 60 mg/ml CHX (Sigma-Aldrich) and with inhibitors
of protein degradation (60 mM cloroquine and 7.5 mM MG132).
These inhibitors were added to the culture medium 36 h after
plating the transfected cells onto Lab-Tek. 2-BP was added during
the time series acquisition.
To analyze the effect of acylation inhibition on the membrane
binding properties of N13GAP-43(C3S), 60 mg/ml CHX was
incorporated to the culture medium during transfection. Then, 5 h
after transfection, 10% FBS was added to the medium and 3 h
later 25, 50 or 150 mM 2-BP were also incorporated. After 0.5 h of
2-BP treatment, the CHX was removed. Finally, after 8 h of CHX
withdrawal, cells were used in live cell imaging or scraped and
used for biochemical experiments.
Electrophoresis and Western Blotting
Electrophoresis, transfer onto the nitrocellulose membrane and
protein immunodetection were performed as described previously
[54]. Anti-GFP polyclonal antibody (Roche Diagnostics, IN, USA)
was used at a dilution of 1:800. Antibodies were detected using
near infrared fluorescence (Li-COR Biotechnology, Lincoln, NE,
USA) with a secondary antibody coupled to IRDye800CW and
diluted to 1:15000 (Li-COR Biotechnology). The relative contri-
bution of the individual bands was calculated using ImageJ
software (National Institute for Health, Bethesda, MA, USA).
Subcellular Fractionation
Cells grown on 60 mm dishes were washed with cold
phosphate-buffered saline (PBS, 140 mM NaCl, 8.4 mM
Na2HPO4, 1.6 mM NaH2PO4, pH 7,5) and harvested by scraping
in PBS containing a protease inhibitor mixture (PIM) with 5 mg/
ml aproptinin, 0.5 mg/ml leupeptin, and 0.7 mg/ml pepstatin
(PBS-PIM). Extracts were centrifuged at 4uC for 5 min at 13000 g
and resuspended in 400 ml of 5 mM Tris-HCl (pH 7.0) (buffer T)
in the presence of protease inhibitors (T-PIM). Pellets were
dispersed by repeated pipetting and vortexing. After 30 min of
incubation in T-PIM, the pellets were passed 60 times through a
25-gauge needle, and nuclear fractions and unbroken cells were
removed by centrifugation at 4uC for 5 min at 600 g. The
supernatants (S fraction) were then ultracentrifuged at 4uC for 1 h
at 400000 g using a TLA 100.3 rotor (Beckman Coulter, Inc., CA,
USA) before being removed and the pellet (P fraction) resuspended
in 400 ml of T-PIM. The proteins in the resulting samples were
precipitated with chloroform/methanol (1:4 v/v) for western blot
analyses.
Expression and Purification of Recombinant APT1 and
APT2
The APT1 and APT2 cDNA containing a Hisx6 tag were
obtained by RT-PCR using specific primers and RNA from the
HeLa and CHO-K1 cells, respectively, and the amplified
fragments were cloned into the BamHI/EcoRI sites of the
bacterial expression vector pRSET-A (Invitrogen, CA, USA).
Transformed Escherichia coli cells were grown at 37uC in Luria-
Bertani (LB) medium containing 15 mg/ml ampicilin to an optical
density of 0.6. Then, a soluble fraction was generated using a high
pressure homogenizer (EmulsiFlex, Avestin, Inc., Ottawa, Ca-
nada), which was centrifugated at 10000 g for 15 min at 4uC.
Hisx6 APT1 and APT2 were then purified from the soluble lysate
using a Ni2+-NTA column (GE Healthcare, Fairfield, VT, USA)
according to the manufacturer’s instructions. The purified proteins
were then desalted using HiTrap desalting columns (GE
Healthcare, Fairfield, VT, USA).
Confocal Microscopy
Confocal images were collected using an Olympus FluoView
FV1000 confocal microscope (Olympus Latin America, Miami,
FL) equipped with a multi-line Argon laser (458, 488 and 514 nm)
and two helium-neon lasers (543 nm and 633 nm, respectively).
YFP was acquired by using laser excitation at 514 nm, a 458/
514 nm excitation dichroic mirror, and a 530–560 nm band pass
emission filter. Cherry protein was acquired with a laser excitation
at 543 nm, a 488/543/633 nm excitation dichroic mirror, and a
560 nm long pass emission filter.
Live Cell Imaging for Deacylation Kinetic Measurements
For deacylation measurements, cells expressing N13GAP-
43(C3S)-YFP were used. The live cell experiments were performed
at 20uC on an Olympus FluoView FV1000 confocal microscope to
minimize vesicular trafficking of GAP-43. After selection of the
cells expressing the protein, images were acquired in the YFP
channel for deacylation kinetic measurements using a 636/
1.42 NA PlanApo objective oil immersion (Olympus) with a 36
digital zoom. Image size was 5126512 pixels with a resolution of
165 mm/pixel, with the scan speed being 10 ms/pixel and the
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pinhole adjusted to obtain an optical slice of 3 mm. Single 3D
images were taken at a frequency of 1 min21 for 30 minutes, with
the acquisition conditions being optimized in order to acquire the
Golgi compartment, to minimize bleaching during acquisition and
to sample as quickly as possible the amount of N13GAP-43(C3S) at
the TGN [29]. All image analysis and the quantification method
were carried out using ImageJ software as described previously
[29].
Palmitoyl-CoA Hydrolase Assay
Palmitoyl-CoA hydrolase assays with purified APT1 or APT2
were performed following a protocol described by Duncan and
Gilman [13] with some modifications.
Small-angle X-ray Scattering (SAXS) Measurements
SAXS was carried out at the SAXS2 beamline at the Brazilian
Synchrotron Light Laboratory (LNLS) at Campinas, Brazil.
Palmitoyl-CoA was resuspended in buffer (50 mM Hepes,
pH 8.0) at 50, 300, 600 and 1775 mM, with the measurement
conditions being 5 minutes of exposure, a sample-detector distance
of 1 m, 1.5 A˚ irradiation, 3061uC. The buffer was measured and
subtracted from the signals. Data was collected by a MARCCD
and radially integrated by using FIT2D V 12.077 at ESRF. The
SAXS curves were generated using the SASFIT free software, and





where l is the X-ray wavelength and 2h is the total scattering
angle.
Supporting Information
Movie S1 Deacylation of N13GAP-43(C3S) at different
doses of 2-BP. CHO-K1 cells expressing N13GAP-43(C3S)-YFP
(pseudocolored green) were incubated in DMEM supplemented
with CHX and protein degradation inhibitors at 20uC on the
microscope stage, following the experimental procedure described
in Fig. 2A. Cells were treated with 25, 50 or 150 mM 2-BP or
DMSO (Control), and time series were acquired (1 frame/min) for
the following 20 min, as indicated in Materials and methods.
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